RT Book, Section
A1 Mascara, Gerard P.
A1 Fojo, Tito
A2 Boyiadzis, Michael M.
A2 Fojo, Tito
SR Print(0)
ID 1187885675
T1 Indications for Growth Factors in Hematology-Oncology
T2 Hematology-Oncology Therapy, 3e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781260117400
LK hemonc.mhmedical.com/content.aspx?aid=1187885675
RD 2024/04/19
AB EpidemiologyFebrile  neutropenia  is  a  major  dose-limiting  toxicity  of  chemotherapy.  Studies  have  demonstrated  that  selective  use  of  colony-stimulating  factors  (CSFs)  in  patients  at  high  risk  for  complications  of  neutropenia  can  enhance  cost-effectiveness  by  reducing  the  risk,  severity,  and  duration  of  febrile  neutropenia